CD33 and acute myeloid leukemia: Although bispecifics like AMV564 (which targets CD33 on AML blasts) together with T cells can directly mediate killing of AML via a MHC independent mechanism, activation of T cells by bispecifics after target engagement can also enhance MHC-dependent killing of AML cells via local release of interferon gamma and subsequent upregulation of MHC class II on AML blasts [12].